Biotalys obtains patents for innovative biofungicide in Europe and the United States

Agricultural biotechnology company Biotalys has announced that it has been granted patents for its first biofungicide, Evoca, by the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). These patents give the company exclusivity over the product’s active ingredient in two key global markets.

According to the company, Evoca is an innovative protein-based solution that promises to help farmers protect their crops against fungal diseases. The protection achieved in Europe and the United States represents an important milestone for the company.

According to Kevin Helash, CEO of Biotalys, the granting of the patents confirms the innovation behind Evoca and provides essential commercial support for the production and distribution of the product. He highlighted that the benefits of the biofungicide will be significant for fruit and vegetable growers, especially those facing challenges with fungal diseases in their crops. Helash stressed that Evoca will be crucial for farmers looking for effective alternatives to pest control.

In addition to Europe and the United States, Biotalys is seeking to expand patent protection for Evoca in other agriculturally relevant markets, including Argentina, Brazil and South Africa. The company has already secured patents in several parts of the world for different aspects of its technology and continues to invest in building its intellectual property.

Evoca is a protein-based biofungicide that has received a new resistance classification by the Fungicide Resistance Action Committee (FRAC). According to the company, the product has been tested in different regions, climates and crops, showing good performance in controlling fungal diseases. The product is currently undergoing regulatory review by the U.S. Environmental Protection Agency (EPA) and the Dutch authority College voor Toelating van Gewasbeschermingsmiddelen en Biociden (CTGB) for its commercialization.

Evoca also serves as the basis for the development of Evoca NG, which is expected to be the first commercially available fungicide based on Biotalys’ Agrobody technology platform. The two products share the same active ingredient. This new generation of biofungicides is expected to make a significant contribution to the future of crop protection by offering more sustainable and innovative solutions for farmers.